Skip to content

Confirming Flower capsule performance characteristics in detection of retained gastric contents

Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/084367
Enrollment
36
Registered
2025-04-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Flower: A controlled, prospective, between-participants study design to assess Flower in detecting the presence or absence of retained gastric contents (RGC), using sedated esophagogast

Sponsors

Endiatx
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Individuals willing and able to sign an IEC approved informed consent form and agrees to comply with study requirements

Exclusion criteria

Exclusion criteria: No history of : Gastrointestinal disorders, Gastroparesis, Prior gastric surgery, Swallowing disorders, Contraindications to EGD or capsule endoscopy and GLP-1 users in the last 3 months.

Design outcomes

Primary

MeasureTime frame
Evaluate the detection of retained gastric contents and assess safety using the Flower Capsule Endoscopy in healthy individuals and GLP-1 receptor agonist users outcome measures will be documented, including the visualization of retained gastric contents; identification of all seven gastric anatomical landmarks fundus, cardia, lesser gastric curvature, lesser gastric curvature, greater gastric curvature, angulus, antrum, and pylorus; evaluation of gastric mucosal visualization; assessment of gastric cleanliness; evaluation of patient tolerance; total water volume intake; number of attempts required for successful capsule swallowing; time to complete the gastric examination; and documentation of any adverse events, such as capsule aspiration, nausea, or pain.Timepoint: 2 Months

Secondary

MeasureTime frame
NATimepoint: NA

Countries

India

Contacts

Public ContactRakesh Kalapala

Asian Institute of Gastroenterology Hospital

drrakeshkalapala@aighospitals.com04042444222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026